Skip to main content
Kyriaki Barmpa on Muck Rack

Kyriaki Barmpa

As seen in: Wiley Online Library, BioRxiv
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Kyriaki

Contact Kyriaki, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Parkinson's Disease Patient‐Specific Striatum Organoids Show Hallmarks of Increased Inflammation

|
By Kyriaki Barmpa, Claudia Saraiva, Alise Zagare
| Wiley Online Library Verified
Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease.1 One of the main processes in the disease development and progression is the degeneration of the dopaminergic neurons in the substantia nigra pars compacta (SNpc) of the midbrain.
Open in Who Shared Issue with article?

Parkinson's disease-related Miro1 mutation induces mitochondrial dysfunction and loss of dopaminergic neurons in vitro and in vivo

|
By Giuseppe Arena, Kyriaki Barmpa, Axel Chemla, Ginevra Sacripanti
| BioRxiv
Abstract The complex and heterogeneous nature of Parkinson disease (PD) is still not fully understood, however, increasing evidence supports mitochondrial impairments as a major driver of neurodegeneration in PD. Recently, the regulator of mitochondrial homeostasis Miro1 has been linked genetically and pathophysiologically to PD.
Open in Who Shared Issue with article?

Age-induced midbrain-striatum assembloids model early phenotypes of Parkinsons disease

|
By Kyriaki Barmpa, Gemma Gomez-Giro, Elisa Gabassi, Claudia Saraiva
| BioRxiv
Abstract Parkinsons disease (PD), one of the most common aging-associated neurodegenerative disorders, is characterised by nigrostriatal pathway dysfunction, caused by the gradual loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) of the midbrain and the dopamine depletion in the striatum. State of the art, human in vitro models are enabling the study of the dopaminergic neurons loss, but not the dysregulation of the dopaminergic network in the nigrostriatal pathway.
Open in Who Shared Issue with article?
See all 4 articles